35414300|t|Targeted Molecular Strategies for Genetic Neurodevelopmental Disorders: Emerging Lessons from Dravet Syndrome.
35414300|a|Dravet syndrome is a severe developmental and epileptic encephalopathy mostly caused by heterozygous mutation of the SCN1A gene encoding the voltage-gated sodium channel alpha subunit Nav1.1. Multiple seizure types, cognitive deterioration, behavioral disturbances, ataxia, and sudden unexpected death associated with epilepsy are a hallmark of the disease. Recently approved antiseizure medications such as fenfluramine and cannabidiol have been shown to reduce seizure burden. However, patients with Dravet syndrome are still medically refractory in the majority of cases, and there is a high demand for new therapies aiming to improve behavioral and cognitive outcome. Drug-repurposing approaches for SCN1A-related Dravet syndrome are currently under investigation (i.e., lorcaserin, clemizole, and ataluren). New therapeutic concepts also arise from the field of precision medicine by upregulating functional SCN1A or by activating Nav1.1. These include antisense nucleotides directed against the nonproductive transcript of SCN1A with the poison exon 20N and against an inhibitory noncoding antisense RNA of SCN1A. Gene therapy approaches such as adeno-associated virus-based upregulation of SCN1A using a transcriptional activator (ETX101) or CRISPR/dCas technologies show promising results in preclinical studies. Although these new treatment concepts still need further clinical research, they offer great potential for precise and disease modifying treatment of Dravet syndrome.
35414300	42	70	Neurodevelopmental Disorders	Disease	MESH:D002658
35414300	94	109	Dravet Syndrome	Disease	MESH:D004831
35414300	111	126	Dravet syndrome	Disease	MESH:D004831
35414300	139	181	developmental and epileptic encephalopathy	Disease	MESH:C562695
35414300	228	233	SCN1A	Gene	6323
35414300	295	301	Nav1.1	Gene	6323
35414300	312	319	seizure	Disease	MESH:D012640
35414300	327	350	cognitive deterioration	Disease	MESH:D003072
35414300	352	375	behavioral disturbances	Disease	MESH:D001523
35414300	377	383	ataxia	Disease	MESH:D001259
35414300	389	412	sudden unexpected death	Disease	MESH:D000080485
35414300	429	437	epilepsy	Disease	MESH:D004827
35414300	519	531	fenfluramine	Chemical	MESH:D005277
35414300	536	547	cannabidiol	Chemical	MESH:D002185
35414300	574	581	seizure	Disease	MESH:D012640
35414300	599	607	patients	Species	9606
35414300	613	628	Dravet syndrome	Disease	MESH:D004831
35414300	815	820	SCN1A	Gene	6323
35414300	829	844	Dravet syndrome	Disease	MESH:D004831
35414300	886	896	lorcaserin	Chemical	MESH:C506658
35414300	898	907	clemizole	Chemical	MESH:C084582
35414300	913	921	ataluren	Chemical	MESH:C515878
35414300	1024	1029	SCN1A	Gene	6323
35414300	1047	1053	Nav1.1	Gene	6323
35414300	1140	1145	SCN1A	Gene	6323
35414300	1224	1230	SCN1A.	Gene	6323
35414300	1263	1285	adeno-associated virus	Species	272636
35414300	1308	1313	SCN1A	Gene	6323
35414300	1349	1355	ETX101	Chemical	-
35414300	1582	1597	Dravet syndrome	Disease	MESH:D004831
35414300	Association	MESH:D004831	6323
35414300	Negative_Correlation	MESH:C515878	6323
35414300	Negative_Correlation	MESH:C515878	MESH:D004831
35414300	Negative_Correlation	MESH:D005277	MESH:D004831
35414300	Negative_Correlation	MESH:D002185	MESH:D004831
35414300	Negative_Correlation	MESH:C084582	MESH:D004831
35414300	Negative_Correlation	MESH:D002185	MESH:D012640
35414300	Negative_Correlation	MESH:C506658	MESH:D004831
35414300	Negative_Correlation	MESH:D005277	MESH:D012640

